SAN DIEGO, March 2, 2011 /PRNewswire/ -- Sequenom, Inc. , today announced the awards of non-qualified stock option grants for a total of 74,450 shares of common stock for six new employees under the company's New Hire Equity Incentive Plan.
(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)
Of these shares, 14,450 have an exercise price of $6.14, which was equal to the closing price of Sequenom's common stock on February 28, and 60,000 have a price of $6.39, the closing price of its common stock on February 15, the dates the options were granted. These options will vest over the course of four years, with 25% vesting on the one-year anniversary of the grant dates and ratably monthly thereafter, subject to continued service through the applicable vesting dates. The stock options have a ten year term, and are granted as an inducement grant to the new employees entering into employment with Sequenom pursuant to Section 5635(c)(4) of the NASDAQ Marketplace Rules.
About Sequenom
Sequenom, Inc. is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a website at http://www.sequenom.com/ to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom website to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.
SEQUENOM® is a trademark of Sequenom, Inc. All other trademarks and service marks are the property of their respective owners.
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the Company's commitment to improving healthcare through revolutionary genetic analysis solutions, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with the Company's ability to develop and commercialize new technologies and products, particularly new technologies such as genetic analysis platforms, noninvasive prenatal diagnostics and laboratory developed tests, reliance upon the collaborative efforts of other parties, the Company's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, government regulation particularly with respect to diagnostic products and laboratory developed tests, obtaining or maintaining regulatory approvals, ongoing litigation and investigations and other risks detailed from time to time in the Company's most recent
Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.
PRN Photo Desk, photodesk@prnewswire.com
Sequenom, Inc.
CONTACT: Paul Maier, CFO of Sequenom, +1-858-202-9000, or Media
Relations, Dan Budwick of Pure Communications, +1-973-271-6085, for Sequenom
Web Site: http://www.sequenom.com/
